Copyright © 2019. Inderes Oy. All rights reserved.

Faron Pharmaceuticals

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
29.4.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Grant of options

Company announcement, 29 April 2021 at 14.45 (EEST)

Tiedotteet
23.4.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Results of the Annual General Meeting and Decisions of the Board of Directors

Company announcement, 23 April 2021 at 15:45 p.m. (EEST)

TURKU, FINLAND - The annual general meeting ("AGM") of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) took place at the premises of Inderes Oy in Helsinki, Finland today, 23 April 2021. The AGM approved all the proposals of the board of directors ("Board") and its committees, set out in the notice of the AGM published on 25 March 2021.

Tiedotteet
23.4.
2021

Faron Pharmaceuticals Oy

 

("Faron" or the "Company")

Board Change

Company announcement, 23 April 2021 at 15:45 EET

TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, is pleased to announce the appointment of Anne Whitaker as a Non-Executive Director of the Company following the passing of all resolutions put to shareholders of the Company at the AGM held earlier today. 

Tiedotteet
29.3.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Appointment of a Broker

 

Company announcement, 29 March 2021 at 9.00 AM (EET)

TURKU - FINLAND - Faron Pharmaceuticals Oy (First North: FARON, AIM: FARN), the clinical stage biopharmaceutical company, is pleased to announce the appointment of Peel Hunt LLP as the Company's sole Broker with effect from today.

 

For more information please contact:

Faron Pharmaceuticals Oy

Dr Markku Jalkanen, Chief Executive Officer

Tiedotteet
25.3.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Exercise of options

Issue of equity

Company announcement, 25 March 2020 at 9.45 AM (EET)

 

Tiedotteet
25.3.
2021

NOTICE OF Faron pharmaceuticals LTD's Annual GENERAL MEETING

Tiedotteet
25.3.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Faron's Annual Report 2020 published

Company announcement, 25 March 2021 at 9.15 AM (EET)
 

TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces that its Annual Report for the year 2020 has been published today.

Tiedotteet
25.3.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Financial statement release January 1 to December 31, 2020

Tiedotteet
22.3.
2021

 Faron Pharmaceuticals Oy

("Faron" or the "Company")

Bexmarilimab (Clevegen) development update
  • Significant survival benefit observed in patients responding to bexmarilimab treatment with risk of death reduced by 88%
  • Gastric cancer becomes sixth tumour cohort to show early signs of clinical efficacy
  • Data monitoring committee recommends dose escalation expansion in all six cohort types besides ongoing colorectal cancer

Company announcement, 22 March 2021 at 9.00 AM (EET)
Inside information

Tiedotteet
25.2.
2021

Faron Pharmaceuticals Oy

("Faron" or the "Company")

Notice of Full-Year Results and Annual Report

Company announcement, 25 February 2021 at 7.00 am GMT / 9.00 am EET

TURKU, FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company, will publish its audited full-year results for the twelve months ended 31 December 2020 on Thursday 25 March 2021 at 7:00 GMT / 9:00 EET. The Annual Report 2020, including audited financial statements for the full year, will be published on the same day.

Faron Pharmaceuticals